Shehnaz K. Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shehnaz K. Hussain has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Asad Umar
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
3 shared publications - Coleman I. Smith
MedStar Georgetown University Hospital 6 Liver Transplant Surgery Washington, District of Columbia
3 shared publications - Ellen Richmond
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
3 shared publications - Kelly A. Benante
10Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
3 shared publications - Laura Kulik
Northwestern Medical Faculty Foundation 5 , Northwestern Medical Group, Chicago, Illinois
3 shared publications - Luz Maria Rodriguez
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
3 shared publications
Latest Publications
- 29 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF11
Individual and Occupational Factors Associated with Receipt of Guideline-Concordant Cancer Screening in California Firefighters
Background: Firefighters face elevated cancer risk due to occupational exposures, yet cancer screening adherence and associated factors remain poorly characterized. Methods: We conducted a cross-sectional analysis of survey data from 3,076 active-duty career firefighters in California without a prior cancer diagnosis. Screening adherence was evaluated against US Preventive Services Task Force (USPSTF) and National Fire Protection Association (NFPA) guidelines for colorectal, breast, cervical, prostate, skin, and lung cancers. Multivariable logistic regression was used to assess the associations between screening receipt and demographic, occupational, behavioral, clinical, and health belief factors. Results: Overall, screen-eligible participants were racially/ethnically diverse (25% Hispanic and 37% non-White), had a mean age of 41 years, and a mean tenure in the fire service of 17 years. Receipt of guideline-concordant screening varied by cancer type and guideline: colorectal (54% NFPA and 68% USPSTF), breast (76%), cervical (75%), prostate (59% NFPA and 78% USPSTF), skin (29%), and lung (ever low-dose CT, 10%). Older age [odds ratio (OR), 1.19–2.65 per 5 years], ≥1 year since a routine doctor’s visit (OR, 0.36–0.58), and family history of cancer (OR, 1.33–1.77) were consistently associated with receipt of cancer screening. Conclusions: Firefighters who were younger (yet within the eligibility age range), had not recently engaged in routine healthcare, and did not have a family history of cancer were less likely to be screened. Impact: This is the first broad characterization of cancer screening among career firefighters, identifying potentially actionable targets for interventions to close screening gaps in this high-risk population.
- 29 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF11
Individual and Occupational Factors Associated with Receipt of Guideline-Concordant Cancer Screening in California Firefighters
Background: Firefighters face elevated cancer risk due to occupational exposures, yet cancer screening adherence and associated factors remain poorly characterized. Methods: We conducted a cross-sectional analysis of survey data from 3,076 active-duty career firefighters in California without a prior cancer diagnosis. Screening adherence was evaluated against US Preventive Services Task Force (USPSTF) and National Fire Protection Association (NFPA) guidelines for colorectal, breast, cervical, prostate, skin, and lung cancers. Multivariable logistic regression was used to assess the associations between screening receipt and demographic, occupational, behavioral, clinical, and health belief factors. Results: Overall, screen-eligible participants were racially/ethnically diverse (25% Hispanic and 37% non-White), had a mean age of 41 years, and a mean tenure in the fire service of 17 years. Receipt of guideline-concordant screening varied by cancer type and guideline: colorectal (54% NFPA and 68% USPSTF), breast (76%), cervical (75%), prostate (59% NFPA and 78% USPSTF), skin (29%), and lung (ever low-dose CT, 10%). Older age [odds ratio (OR), 1.19–2.65 per 5 years], ≥1 year since a routine doctor’s visit (OR, 0.36–0.58), and family history of cancer (OR, 1.33–1.77) were consistently associated with receipt of cancer screening. Conclusions: Firefighters who were younger (yet within the eligibility age range), had not recently engaged in routine healthcare, and did not have a family history of cancer were less likely to be screened. Impact: This is the first broad characterization of cancer screening among career firefighters, identifying potentially actionable targets for interventions to close screening gaps in this high-risk population.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels
Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the United States. The primary outcome was the change in serum α-fetoprotein (AFP)-L3% from baseline to 6 months. Secondary biomarker endpoints include changes in serum AFP, serum IL6, serum deoxycholic acid, liver stiffness, Model for End-Stage Liver Disease score, and Fibrosis-4 index score. Comparisons were made using paired t tests or the Wilcoxon rank-sum test. Forty-five participants completed the intervention and final study assessments [mean age, 58 years; female, 42%; Asian, 2.2%; Black or African American, 11%; White, 87%; Hispanic or Latino, 51%; Child-Pugh (CP) A, 69%; CP B, 16%]. Of 45 participants, 10 (22%) had detectable AFP-L3%, which did not differ between the intervention arms. Serum IL6 levels, detectable in all participants, decreased significantly in the simvastatin group compared with the placebo group (P = 0.02). The number and grade of adverse events did not differ between groups. In this randomized controlled trial, simvastatin was well tolerated in patients with liver cirrhosis but did not result in a decrease in AFP-L3%, potentially owing to the low number of participants with detectable AFP/AFP-L3%. Simvastatin did result in a decrease in IL6, offering one potential anticancer mechanism of simvastatin in the setting of cirrhosis. Prevention Relevance:Increasing liver cancer incidence parallels cirrhosis related to nonalcoholic steatohepatitis. Statins have the potential to arrest cirrhosis progression and prevent liver cancer. In a phase IIB trial randomizing patients with cirrhosis to simvastatin versus placebo, we found that simvastatin decreased the inflammation biomarker IL6, but not the primary endpoint of AFP-L3.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels
Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the United States. The primary outcome was the change in serum α-fetoprotein (AFP)-L3% from baseline to 6 months. Secondary biomarker endpoints include changes in serum AFP, serum IL6, serum deoxycholic acid, liver stiffness, Model for End-Stage Liver Disease score, and Fibrosis-4 index score. Comparisons were made using paired t tests or the Wilcoxon rank-sum test. Forty-five participants completed the intervention and final study assessments [mean age, 58 years; female, 42%; Asian, 2.2%; Black or African American, 11%; White, 87%; Hispanic or Latino, 51%; Child-Pugh (CP) A, 69%; CP B, 16%]. Of 45 participants, 10 (22%) had detectable AFP-L3%, which did not differ between the intervention arms. Serum IL6 levels, detectable in all participants, decreased significantly in the simvastatin group compared with the placebo group (P = 0.02). The number and grade of adverse events did not differ between groups. In this randomized controlled trial, simvastatin was well tolerated in patients with liver cirrhosis but did not result in a decrease in AFP-L3%, potentially owing to the low number of participants with detectable AFP/AFP-L3%. Simvastatin did result in a decrease in IL6, offering one potential anticancer mechanism of simvastatin in the setting of cirrhosis. Prevention Relevance:Increasing liver cancer incidence parallels cirrhosis related to nonalcoholic steatohepatitis. Statins have the potential to arrest cirrhosis progression and prevent liver cancer. In a phase IIB trial randomizing patients with cirrhosis to simvastatin versus placebo, we found that simvastatin decreased the inflammation biomarker IL6, but not the primary endpoint of AFP-L3.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels
Supplemental Table 1. Study Participants Representativeness.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels
Supplemental Table 1. Study Participants Representativeness.
- 6 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19  (8) , OF1-OF9
Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels
Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the United States. The primary outcome was the change in serum α-fetoprotein (AFP)-L3% from baseline to 6 months. Secondary biomarker endpoints include changes in serum AFP, serum IL6, serum deoxycholic acid, liver stiffness, Model for End-Stage Liver Disease score, and Fibrosis-4 index score. Comparisons were made using paired t tests or the Wilcoxon rank-sum test. Forty-five participants completed the intervention and final study assessments [mean age, 58 years; female, 42%; Asian, 2.2%; Black or African American, 11%; White, 87%; Hispanic or Latino, 51%; Child-Pugh (CP) A, 69%; CP B, 16%]. Of 45 participants, 10 (22%) had detectable AFP-L3%, which did not differ between the intervention arms. Serum IL6 levels, detectable in all participants, decreased significantly in the simvastatin group compared with the placebo group (P = 0.02). The number and grade of adverse events did not differ between groups. In this randomized controlled trial, simvastatin was well tolerated in patients with liver cirrhosis but did not result in a decrease in AFP-L3%, potentially owing to the low number of participants with detectable AFP/AFP-L3%. Simvastatin did result in a decrease in IL6, offering one potential anticancer mechanism of simvastatin in the setting of cirrhosis. Prevention Relevance: Increasing liver cancer incidence parallels cirrhosis related to nonalcoholic steatohepatitis. Statins have the potential to arrest cirrhosis progression and prevent liver cancer. In a phase IIB trial randomizing patients with cirrhosis to simvastatin versus placebo, we found that simvastatin decreased the inflammation biomarker IL6, but not the primary endpoint of AFP-L3.
- 6 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19  (8) , OF1-OF9
Simvastatin Treatment in Patients with Liver Cirrhosis: A Phase II Randomized Placebo-Controlled Trial Shows Reduction in IL6 Levels
Hepatocellular carcinoma (HCC) is a lethal cancer with an increasing burden. Few clinical trials have evaluated preventive strategies for HCC in high-risk patients with liver cirrhosis. Observational studies show that statins are associated with a reduced HCC risk although a causal link has yet to be established. This multicenter randomized double-blinded, placebo-controlled phase II trial of 40 mg/day oral simvastatin to reduce the likelihood of hepatocarcinogenesis was conducted at four sites in the United States. The primary outcome was the change in serum α-fetoprotein (AFP)-L3% from baseline to 6 months. Secondary biomarker endpoints include changes in serum AFP, serum IL6, serum deoxycholic acid, liver stiffness, Model for End-Stage Liver Disease score, and Fibrosis-4 index score. Comparisons were made using paired t tests or the Wilcoxon rank-sum test. Forty-five participants completed the intervention and final study assessments [mean age, 58 years; female, 42%; Asian, 2.2%; Black or African American, 11%; White, 87%; Hispanic or Latino, 51%; Child-Pugh (CP) A, 69%; CP B, 16%]. Of 45 participants, 10 (22%) had detectable AFP-L3%, which did not differ between the intervention arms. Serum IL6 levels, detectable in all participants, decreased significantly in the simvastatin group compared with the placebo group (P = 0.02). The number and grade of adverse events did not differ between groups. In this randomized controlled trial, simvastatin was well tolerated in patients with liver cirrhosis but did not result in a decrease in AFP-L3%, potentially owing to the low number of participants with detectable AFP/AFP-L3%. Simvastatin did result in a decrease in IL6, offering one potential anticancer mechanism of simvastatin in the setting of cirrhosis. Prevention Relevance: Increasing liver cancer incidence parallels cirrhosis related to nonalcoholic steatohepatitis. Statins have the potential to arrest cirrhosis progression and prevent liver cancer. In a phase IIB trial randomizing patients with cirrhosis to simvastatin versus placebo, we found that simvastatin decreased the inflammation biomarker IL6, but not the primary endpoint of AFP-L3.
- 12 March 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71  (2) , 108333
Quality of Cancer Care in California After Full Implementation of the Affordable Care Act: Findings From a Population-Based Study
- 12 March 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71  (2) , 108333
Quality of Cancer Care in California After Full Implementation of the Affordable Care Act: Findings From a Population-Based Study
- Open Access
- 14 March 2022
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 801805
Cancer Screening Practices Among Healthcare Workers During the COVID-19 Pandemic
The COVID-19 pandemic has the potential to impact long-standing efforts to increase adherence to cancer screening guidelines. Healthcare workers (HCWs) experienced significant hardship, but generally have greater access to preventive services, making them a particularly relevant population in which to understand cancer screening behaviors during the pandemic. We report data from 794 HCWs enrolled in the NCI-funded Serological Sciences Network for Coronavirus Associations and Longitudinal Evaluation Study from December 2020 to April 2021. Participants reported lifestyle and screening behaviors during relevant look-back periods which included the pandemic timeframe. Among women between the ages of 40 and 74, 25.7% were overdue for mammographic breast cancer screening. Among participants 50–75 years old, 38.9% were overdue for colorectal cancer screening. The proportion over-due varied according to race/ethnicity. Lifetime low-dose computed tomography lung cancer screening among HCWs age 50–80 years who were smokers was 10.9%. Strategies to address screening disruptions are needed to minimize the impact of later stage of diagnosis.
- 14 March 2022
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 10, 801805
Open AccessCancer Screening Practices Among Healthcare Workers During the COVID-19 Pandemic
The COVID-19 pandemic has the potential to impact long-standing efforts to increase adherence to cancer screening guidelines. Healthcare workers (HCWs) experienced significant hardship, but generally have greater access to preventive services, making them a particularly relevant population in which to understand cancer screening behaviors during the pandemic. We report data from 794 HCWs enrolled in the NCI-funded Serological Sciences Network for Coronavirus Associations and Longitudinal Evaluation Study from December 2020 to April 2021. Participants reported lifestyle and screening behaviors during relevant look-back periods which included the pandemic timeframe. Among women between the ages of 40 and 74, 25.7% were overdue for mammographic breast cancer screening. Among participants 50–75 years old, 38.9% were overdue for colorectal cancer screening. The proportion over-due varied according to race/ethnicity. Lifetime low-dose computed tomography lung cancer screening among HCWs age 50–80 years who were smokers was 10.9%. Strategies to address screening disruptions are needed to minimize the impact of later stage of diagnosis.
- Open Access
- 20 November 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67  (8) , 3831-3841
Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
Background Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. Methods Patients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively. Results A total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02–54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60–13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06–9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32–20.27), methionine (HR = 9.97, 95% CI = 3.02–32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84–17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23–53.48). Conclusion Alloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis.
- 20 November 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67  (8) , 3831-3841
Open AccessDuodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
Background Hepatocellular carcinoma (HCC) is rapidly increasing in the U.S. and is a leading cause of mortality for patients with cirrhosis. Discovering novel biomarkers for risk stratification of HCC is paramount. We examined biomarkers of the gut-liver axis in a prospective multicenter cohort. Methods Patients with cirrhosis without a history of HCC were recruited between May 2015 and March 2020 and prospectively followed at 3 tertiary care hospitals in Los Angeles. Microbiome analysis was performed on duodenal biopsies and metabolomic analysis was performed on serum samples, collected at the time of enrollment. Optimal microbiome-based survival analysis and Cox proportional hazards regression analysis were used to determine microbiota and metabolite associations with HCC development, respectively. Results A total of 227 participants with liver cirrhosis contributed a total of 459.58 person-years of follow-up, with 14 incident HCC diagnoses. Male sex (HR = 7.06, 95% CI = 1.02–54.86) and baseline hepatic encephalopathy (HE, HR = 4.65, 95% CI = 1.60–13.52) were associated with developing HCC over follow-up. Adjusting for age, sex, baseline HE, and alkaline phosphatase, an increased risk of HCC were observed for participants with the highest versus lowest three quartiles for duodenal Alloprevotella (HR = 3.22, 95% CI = 1.06–9.73) and serum taurocholic acid (HR = 6.87, 95% CI = 2.32–20.27), methionine (HR = 9.97, 95% CI = 3.02–32.94), and methioninesulfoxide (HR = 5.60, 95% CI = 1.84–17.10). Being in the highest quartile for Alloprevotella or methionine had a sensitivity and specificity for developing HCC of 85.71% and 60.56%, respectively, with an odds ratio of 10.92 (95% CI = 2.23–53.48). Conclusion Alloprevotella and methionine, methioninesulfoxide, and taurocholic acid predicted future HCC development in a high-risk population of participants with liver cirrhosis.
- 15 April 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72  (8_Suppleme) , 551
Abstract 551: Human papillomavirus (HPV) infection characteristics in a cohort of men who have sex with men (MSM) during long-term follow-up
Purpose: To describe sociodemographic, HIV and HPV infection characteristics in MACS men. Background: HPV-associated invasive anal cancer (IAC) is a health crisis for gay, bisexual, transgender and other MSM. MSM show 20-40 fold higher risk for IAC, especially within the context of HIV and since the introduction of combined antiretroviral therapy (CART) (1-4). Experts classify high-risk HPVs as having sufficient (Group 1) or limited (Group 2) evidence of causality for cervical cancer. The prevalence of these HPVs in MSM may inform risk for cancer. Methods: For 1262 MACS men evaluated at visits 56-58, Dacron swab specimens were tested for HPV using the Linear Array assay (Roche Diagnostic Laboratories, Pleasanton, CA). HPVs were classified as high-risk Groups 1 (HPV16/18/31/33/35/39/45/51/52/56/58/59) and 2 (HPV26/30/34/53/66/67/68/69/70/73/82), and low-risk HPVs (HPV6/11/40/42/54/56/61/62/64/70/71/72/82/83/84/IS39/CP6108). Descriptive and tabular analyses were used to explore the data. Poisson regression with robust error variance analyses were used to estimate prevalence ratios (PR, (95% confidence intervals)) comparing HPV groupings in both univariate and multivariate models using the SAS 9.2 GENMOD procedure (SAS Institute, Cary, North Carolina, USA). Final models included age and race, period-specific self-reported number of sexual partnerships, HIV-infection status, and CD4+ count (cell/mm3) among HIV-infected participants. Results: Participants are best described as older (µ=55 (9.4), M=55.6), and although Whites comprised >50% of both groups, HIV-infected men were >2 times as likely as uninfected men to report being Black, 25% vs. 10%. On average, the prevalence of all HPVs was 1.35-1.91 fold higher among HIV-infected than -uninfected men. Trend analyses showed CD4+ cell count was inversely associated with HPV Group 2 prevalence alone (pCitation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 551. doi:1538-7445.AM2012-551
- 15 April 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72  (8_Suppleme) , 551
Abstract 551: Human papillomavirus (HPV) infection characteristics in a cohort of men who have sex with men (MSM) during long-term follow-up
Purpose: To describe sociodemographic, HIV and HPV infection characteristics in MACS men. Background: HPV-associated invasive anal cancer (IAC) is a health crisis for gay, bisexual, transgender and other MSM. MSM show 20-40 fold higher risk for IAC, especially within the context of HIV and since the introduction of combined antiretroviral therapy (CART) (1-4). Experts classify high-risk HPVs as having sufficient (Group 1) or limited (Group 2) evidence of causality for cervical cancer. The prevalence of these HPVs in MSM may inform risk for cancer. Methods: For 1262 MACS men evaluated at visits 56-58, Dacron swab specimens were tested for HPV using the Linear Array assay (Roche Diagnostic Laboratories, Pleasanton, CA). HPVs were classified as high-risk Groups 1 (HPV16/18/31/33/35/39/45/51/52/56/58/59) and 2 (HPV26/30/34/53/66/67/68/69/70/73/82), and low-risk HPVs (HPV6/11/40/42/54/56/61/62/64/70/71/72/82/83/84/IS39/CP6108). Descriptive and tabular analyses were used to explore the data. Poisson regression with robust error variance analyses were used to estimate prevalence ratios (PR, (95% confidence intervals)) comparing HPV groupings in both univariate and multivariate models using the SAS 9.2 GENMOD procedure (SAS Institute, Cary, North Carolina, USA). Final models included age and race, period-specific self-reported number of sexual partnerships, HIV-infection status, and CD4+ count (cell/mm3) among HIV-infected participants. Results: Participants are best described as older (µ=55 (9.4), M=55.6), and although Whites comprised >50% of both groups, HIV-infected men were >2 times as likely as uninfected men to report being Black, 25% vs. 10%. On average, the prevalence of all HPVs was 1.35-1.91 fold higher among HIV-infected than -uninfected men. Trend analyses showed CD4+ cell count was inversely associated with HPV Group 2 prevalence alone (pCitation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 551. doi:1538-7445.AM2012-551